This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

US FTC’s Section 13(b) powers must be restored to tackle anticompetitive drug pricing practices, senators told

By Khushita Vasant ( May 5, 2022, 22:19 GMT | Insight) -- The Federal Trade Commission must act to combat anticompetitive drug pricing practices by pharmacy benefit managers in the US, senators were told today. Congress also must pass laws that restore the agency’s powers to collect monetary redress for consumers, experts testified at a commerce committee panel hearing....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections